Apricot Capital is a venture capital firm founded in 2015 and based in Shanghai, China, deeply rooted in China's healthcare ecosystem. The firm specializes in incubating and scaling early- and growth-stage companies in biotech, medtech, and life sciences to address unmet global clinical needs.
Deal activity increased 500% year-over-year (6 deals in the last 12 months). Their most common stage is series-a (42% of deals). Average disclosed round size is $61.0M (across 16 rounds with reported amounts).
Portfolio
16
Fund Size
—
Top Stage
Series A
Last 12 Mo
6
Team
Arthur Qiang
Managing Partner Ph. D. CFA FRM
Crystal Liu
Managing Partner Dr. PH
William Mao
Managing Partner MS / EMBA
Haigang Chen
Partner M. D
Wei Ding
Partner Ph.D.
Yakun Ding
Partner MS
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 ClinChoice | Seed | $150M | Sep 2026 |
| VVivacta Biotechnology | Series A | $50M | Apr 2026 |
 Vivacta | Series A | $50M | Apr 2026 |
| VVivaTides Therapeutics | Series A | $54M | Apr 2026 |
| VVivaTides Therapeutics | Seed | — | Apr 2026 |
 Vibrant Therapeutics | Series C | $61M | Jan 2026 |
 QL Biopharm | Unknown | $200M | Jan 2026 |
 Qi Biodesign | Series A | $75M | Dec 2024 |
| MMediLink Therapeutics | Series B | $70M | Mar 2022 |
 Geniebook | Series A | $16.6M | Oct 2021 |
| MMediLink | Series A | — | Mar 2021 |
| MMediLink Therapeutics | Series A | $50M | Mar 2021 |
| SShengsheng | Series C | — | Jan 2021 |
| AAmbrx Inc | Unknown | $45M | Nov 2020 |
| SShengsheng | Series B | — | Jan 2020 |
| Geniebook | Series A | $1.1M | Jan 2019 |
| SShengsheng | Series A | — | Jan 2018 |
 ShengSheng | Series A | — | Jan 2018 |
| SShengsheng | Seed | — | Jan 2017 |
| AAmbrx Inc | Unknown | $45M | Jan 2016 |
| AAwe.sm | Unknown | $4M | Jan 2011 |
| GGolden Duck | Unknown | — | — |
| BBellen Chemistry | Unknown | $30M | — |
| Qi Biodesign | Seed | $75M | — |
Top Co-Investors
Last updated: 20 October 2026